title: Factor X activator from Vipera lebetina snake venom, molecular characterization and substrate specificity.
abstract: Our studies of the venom from the Levantine viper Vipera lebetina have demonstrated the existence of both coagulants and anticoagulants of the hemostatic system in the same venom. We showed that V. lebetina venom contains factor X activator (VLFXA) and factor V activator, fibrinolytic enzymes. VLFXA was separated by gel filtration on Sephadex G-100 superfine and ion exchange chromatography on CM-cellulose and on TSK-DEAE (for HPLC) columns. VLFXA is a glycoprotein composed of a heavy chain (57.5 kDa) and two light chains (17.4 kDa and 14.5 kDa) linked by disulfide bonds. VLFXA has multiple molecular forms distinguished by their isoelectric points. The differences in their pI values may be caused by dissimilarities in the respective charged carbohydrate content or in the primary sequence of amino acids. We synthesized 6-9 amino acid residues containing peptides according to physiological cleavage regions of human factor X and human factor IX. The peptides (Asn-Asn-Leu-Thr-Arg-Ile-Val-Gly-Gly - factor X fragment, and Asn-Asp-Phe-Thr-Arg-Val-Val-Gly-Gly - factor IX fragment) were used as substrates for direct assay of VLFXA. Cleavage products of peptide hydrolysis and the molecular masses of cleavage products of human factor X were determined by MALDI-TOF MS. The MALDI-TOF MS was highly efficient for the recovery and identification of peptides released by VLFXA hydrolysis. We can conclude that VLFXA cleaves the Arg(52)-Ile(53) bond in the heavy chain of human factor X and the Arg(226)-Val(227) bond in human factor IX precursor. VLFXA could not activate prothrombin nor had any effect on fibrinogen, and it had no arginine esterase activity toward benzoylarginine ethyl ester.
authors.affiliation: National Institute of Chemical Physics and Biophysics, Akadeemia tee 23, Tallinn 12618, Estonia.
authors.forename: E
authors.initials: E
authors.lastname: Siigur
authors.forename: K
authors.initials: K
authors.lastname: Tõnismägi
authors.forename: K
authors.initials: K
authors.lastname: Trummal
authors.forename: M
authors.initials: M
authors.lastname: Samel
authors.forename: H
authors.initials: H
authors.lastname: Vija
authors.forename: J
authors.initials: J
authors.lastname: Subbi
authors.forename: J
authors.initials: J
authors.lastname: Siigur
mesh_terms: D002850:Chromatography, Gel; D002852:Chromatography, Ion Exchange; D003546:Cysteine Endopeptidases / Q000737:chemistry / Q000302:isolation & purification* / Q000378:metabolism; D004591:Electrophoresis, Polyacrylamide Gel; D005170:Factor X / Q000378:metabolism; D006801:Humans; D007525:Isoelectric Focusing; D008666:Metalloendopeptidases / Q000302:isolation & purification; D008970:Molecular Weight; D009363:Neoplasm Proteins; D010446:Peptide Fragments / Q000032:analysis; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; D013379:Substrate Specificity; D014757:Viper Venoms / Q000201:enzymology*
chemical_list: D009363:Neoplasm Proteins; D010446:Peptide Fragments; D014757:Viper Venoms; D005170:Factor X; D003546:Cysteine Endopeptidases; C030910:cancer procoagulant; D008666:Metalloendopeptidases